Treatment of Severe Widespread Itchy Rash
For a severe itchy rash covering most of the body, initiate treatment with regular emollients applied at least once daily to the entire body, combined with medium-to-high potency topical corticosteroids (such as betnovate, elocon, or dermovate ointment to the body; 1-2.5% hydrocortisone or eumovate to the face), plus oral antihistamines for symptomatic relief of pruritus. 1
Immediate Management Approach
First-Line Topical Therapy
- Apply emollients liberally and frequently (at least once daily to the whole body, ideally after bathing) to restore the skin barrier and reduce transepidermal water loss 1
- For widespread involvement, use approximately 100g per 2 weeks for trunk and 100g per 2 weeks for both legs in adults 1
- Use soap substitutes (aqueous emollients) instead of regular soaps, as normal soaps are dehydrating and worsen xerotic skin 1
- Avoid alcohol-containing lotions or gels; instead use oil-in-water creams or ointments 1
Topical Corticosteroid Selection by Body Area
- Face and neck: Use mild-to-moderate potency steroids (1-2.5% hydrocortisone or eumovate ointment) 1
- Body/trunk: Use potent steroids (betnovate, elocon, or dermovate ointment) applied once or twice daily 1
- Apply topical steroids for 2-3 weeks initially, then reassess 1
- Hydrocortisone can be applied not more than 3-4 times daily for itching, inflammation, and rashes 2
Oral Antihistamines for Pruritus
- Prescribe oral antihistamines such as cetirizine, loratadine, fexofenadine, or clemastine for symptomatic itch relief 1
- Note that only sedating antihistamines provide benefit through their sedative properties, particularly useful for severe pruritus affecting sleep 1
- Non-sedating antihistamines have limited value for itch in eczematous conditions 1
- Warn patients about sedative effects on driving and operating machinery 1
When to Escalate to Systemic Corticosteroids
Indications for Oral Steroids
If the rash is severe (covering >30% body surface area) with substantial symptoms or if topical therapy fails after 2 weeks, escalate to systemic treatment 1
Oral prednisolone 0.5-1 mg/kg daily should be initiated for severe widespread rash with significant symptoms 1, 3
- For mild-to-moderate severity: Start 0.5-1 mg/kg prednisolone once daily for 3 days, then wean over 1-2 weeks 1
- For severe symptoms: Consider IV methylprednisolone 0.5-1 mg/kg, converting to oral steroids on response, with weaning over 2-4 weeks 1
Additional Symptomatic Measures
For Severe Pruritus
- Urea- or polidocanol-containing lotions can soothe pruritus when applied topically 1
- Menthol-based creams may provide additional relief for severe itching 4
- Consider bathing with emollient bath oils for both cleansing and hydrating the skin 1
Avoidance Measures
- Avoid hot showers and excessive bathing, which remove natural skin lipids 1
- Keep nails short to minimize excoriation 1
- Avoid irritant clothing such as wool next to skin; recommend cotton clothing 1
- Avoid extremes of temperature 1
When to Seek Specialist Input
Dermatology Referral Indicated If:
- No improvement after 2 weeks of appropriate topical therapy 1
- Rash worsens despite treatment 1
- Diagnostic uncertainty exists 1
- Signs of secondary infection develop (crusting, weeping, pustules) 1
- Consider skin biopsy and clinical photography for severe or atypical presentations 1
Important Caveats
Infection Surveillance
- Look for signs of bacterial superinfection: crusting, weeping, or pustulation 1
- If infection suspected, add topical or oral antibiotics (such as tetracycline for ≥2 weeks) in addition to other treatments 1
- Bacterial swabs should be taken if patients don't respond to treatment 1
Steroid Safety
- Use the least potent preparation required to control symptoms 1
- Short-term application only for potent/very potent steroids (2-3 weeks maximum) 1
- Avoid prolonged use of potent steroids on the face 1
- When symptoms improve, attempt to stop steroids for short periods 1
This structured approach prioritizes rapid symptom control while minimizing adverse effects, with clear escalation pathways if initial therapy fails.